Latest news
Kidney Cancer Has a New Post-Immunotherapy Standard. Survival Is Not Settled.
FDA has approved belzutifan plus lenvatinib after PD-1 or PD-L1 therapy in advanced clear-cell renal cell carcinoma. The combination improved progression-free survival and response against cabozantinib. Overall survival did not cross the statistical line.
Measles Deaths in England Expose the Cost of Missed Protection
Europe’s AMR Strategy Depends on the Lab Result Being Right
Heatwaves are emerging as a cardiovascular risk factor, prompting calls for stronger climate adaptation and public health policies
Eli Lilly’s retatrutide could reset obesity care, but rising demand and grey-market access are testing regulators and health systems
Metabolic health is no longer just a clinic problem. It is a city, climate and equity problem
Can AstraZeneca challenge the obesity market leaders? New GLP-1 data signal growing ambitions beyond oncology
AMR Stewardship Starts Before the Antibiotic Is Prescribed
HEARTS 2.0: Latin America moves beyond hypertension and into cardio-kidney-metabolic care
IPM Brief – Issue 2 | The Gatekeepers Are Moving
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.